Cougar Biotechnology to Present at Bank of America and Merrill Lynch 2009 Health Care Conference

Cougar Biotechnology, Inc. (NASDAQ:CGRB) today announced that Alan H. Auerbach, Chief Executive Officer and President of Cougar, will present at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, at 11:20 a.m. EDT at The Palace Hotel in New York City. Mr. Auerbach will provide a company overview and update on the status of Cougar�s current clinical development programs.

Interested investors may access a live audio webcast by visiting the Investor Relations section of the Company�s Web site at www.cougarbiotechnology.com. The presentation will be archived on the Web site and available for 30 days.

About Cougar Biotechnology

Cougar Biotechnology, Inc. is a Los Angeles-based biotechnology company, established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, a targeted inhibitor of the 17-alpha hydroxylase/c17,20 lyase enzyme, which is currently being studied in Phase III clinical trials in prostate cancer and a Phase I/II trial in breast cancer; CB3304, an inhibitor of microtubule dynamics, which is currently in a Phase I trial in multiple myeloma; and CB1089, an analog of vitamin D, which has been clinically tested in a number of solid tumor types.

Further information about Cougar can be found at www.cougarbiotechnology.com.

Cougar Biotechnology (MM) (NASDAQ:CGRB)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024